Discover unutilized innovative drug seeds in Japan
We discover innovative intellectual property, research result, and know-how that has been unutilized in Japanese pharmaceuticals, biotech companies, and academia and advance them into the early stage of drug development (non-clinical studies and early-phase clinical trials).
Develop novel medicines for refractory diseases
We develop novel medicines for refractory diseases (mainly immune-mediated diseases) and deliver them to patients in the world.
The recent global open innovation trend highlighted the following problems in drug discovery in Japan:
Unutilized innovative drug seeds
Recently, many Japanese pharmaceutical companies have made a strategic
review of focused therapeutic areas and terminated research and development
programs in non-focused therapeutic areas. Accordingly, a number of promising
drug seeds is left unused in Japan.
Lack of a professional team specialized in early stage of drug development
Under immature venture business environment in Japan, biotech companies and
academia do not have access to sufficient funds and expertise on drug
development. Therefore, it is quite difficult for them to conduct the development of
non-clinical studies (including the studies belonging to GLP*) through early-phase
clinical trials. Under such circumstances, to deliver novel medicines to patients, a
company with expertise in early stage of drug development is particularly required.
Curadim Pharma was established to solve these problems. We discover unutilized
innovative drug seeds in Japan and enhance the flow of drug development as a company
specialized in conducting the early stage of drug development (non-clinical studies and
early-phase clinical trials). Through providing such solutions, we are committed to deliver
treatments for refractory diseases with high unmet medical needs to patients in the world.
*An abbreviation of “Good Laboratory Practice,” which refers to standards for ensuring reliability of data by appropriately conducting non-clinical safety studies.